Incb001158
WebCB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. WebPresentation details: Date: Available starting on Friday, January 15 at 5:00 a.m. Pacific …
Incb001158
Did you know?
Web1621 - Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in … http://www.calithera.com/wp-content/uploads/2024/09/ESMO2024-Abstract-1621_Presentation-440O-Slide-Deck-24Sep2024_FINAL_NO-speaker-notes.pdf
WebOct 1, 2024 · Phase I study of the arginase inhibitor INCB001158 (1158) alone and in … WebMay 10, 2024 · The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.
WebOverview. NCI Definition [ 1 ]: An orally available inhibitor of arginase, a manganese … http://www.calithera.com/wp-content/uploads/2024/01/Arginase-1158-203-Poster.pdf
WebBank Identification Number (“BIN”) or Issuer identification number (“IIN”) is the first six …
WebMay 6, 2024 · INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Sponsor Incyte Corporation (Industry) Overall Status Completed CT.gov ID NCT03837509 Collaborator (none) 15 Enrollment 29 Locations 3 Arms 30.3 Actual Duration (Months) 0.5 Patients Per Site 0 … granite school californiaWebCB-1158 (INCB001158) is a potent, and selective inhibitor of human arginase I (IC₅₀ = 98 nM), an immune-mediated anti-tumor agent. Displays potential for anti-tumor activity in renal cell cancer, breast cancer, non-small cell lung cancer, acute myeloid leukemia, etc. A potent, and selective human arginase I inhibitor Formula: C₁₁H₂₂BN₃O₅ granite school district calendar 2017WebFeb 24, 2024 · incb001158. Showing 1 - 3 of 3. Trials per page: STUDY. CONDITIONS. INTERVENTIONS. LOCATIONS. LAST UPDATED Advanced Solid Tumors, Metastatic Solid Tumors Trial in Chuo Ku, Kashiwa (Retifanlimab, INCB001158, Retifanlimab + INCB001158) Completed. Advanced Solid Tumors; Metastatic Solid Tumors ... granite school district board of educationWebAug 24, 2024 · Explanation A problem occurred during the IPL of a partition. Response The … chino hills edd sdi officeWebJan 11, 2024 · INCB001158 Biliary Tract Cancer Data to be Presented at 2024 Virtual ASCO Gastrointestinal Cancers Symposium Published: Jan 11, 2024 SOUTH SAN FRANCISCO, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc.. granite school district bus routesWebNov 28, 2024 · Drug: INCB001158 Drug: Epacadostat Drug: Pembrolizumab Study Type Interventional Enrollment (Actual) 5 Phase Phase 2 Phase 1 Contacts and Locations This section provides the contact details for those conducting the study, and information on where this study is being conducted. Study Locations United States Alabama chino hills emergency vetWeb• INCB001158 is a small-molecule arginase inhibitor that restores arginine levels and alleviates myeloid-derived immunosuppression in the tumor microenvironment Primary Endpoints •Safety, tolerability, and RP2D of INCB001158 in combination with gemcitabine/cisplatin •ORR Secondary Endpoints •DOR, DCR, PFS Other Endpoints PK ... chino hills elementary schools